NCT03108924View on ClinicalTrials.gov

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

September 3, 2017

Study Completion Date

September 13, 2017

Conditions
Renal Insufficiency
Interventions
DRUG

Gefapixant

After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.

Trial Locations (2)

32809

Orlando Clinical Research Center ( Site 0002), Orlando

33014

Clinical Pharmacology of Miami ( Site 0001), Hialeah

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03108924 - The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026) | Biotech Hunter | Biotech Hunter